Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: harinstein me. JACC Heart Fail. 2013 Dec;1(6):488-96. doi: 10.1016/j.jchf.2013.08.005. Epub 2013 Dec 2. JACC Heart Fail. 2013. PMID: 24622000 Free article. Clinical Trial.
Site selection for heart failure clinical trials in the USA.
Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O'Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M. Harinstein ME, et al. Heart Fail Rev. 2015 Jul;20(4):375-83. doi: 10.1007/s10741-015-9473-z. Heart Fail Rev. 2015. PMID: 25649127
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: harinstein me. Am J Cardiol. 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21. Am J Cardiol. 2012. PMID: 22917555 Clinical Trial.
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Khan H, et al. Among authors: harinstein me. Heart Fail Rev. 2009 Dec;14(4):277-87. doi: 10.1007/s10741-009-9136-z. Epub 2009 Feb 24. Heart Fail Rev. 2009. PMID: 19238540 Review.
56 results